GeoVax Labs, Inc. (GOVX)
US — Healthcare Sector
Automate Your Wheel Strategy on GOVX
With Tiblio's Option Bot, you can configure your own wheel strategy including GOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?
GOVX
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About GeoVax Labs, Inc. (GOVX)
- IPO Date 2020-09-25
- Website https://www.geovax.com
- Industry Biotechnology
- CEO David Alan Dodd
- Employees 17
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.